Processa Historical Financial Ratios
| PCSA Stock | USD 1.16 0.18 18.37% |
Processa Pharmaceuticals is promptly reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 3.62, Invested Capital of 0.0, Average Payables of 173.8 K or Stock Based Compensation To Revenue of 1.41 will help investors to properly organize and evaluate Processa Pharmaceuticals financial condition quickly.
Processa |
About Processa Financial Ratios Analysis
Processa PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Processa Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Processa financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Processa Pharmaceuticals history.
Processa Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Processa Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Processa Pharmaceuticals sales, a figure that is much harder to manipulate than other Processa Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Processa Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Processa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.At present, Processa Pharmaceuticals' Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 17.64, whereas PTB Ratio is forecasted to decline to 1.67.
| 2023 | 2024 (projected) | Payables Turnover | 7.12E-4 | 6.77E-4 | Days Of Inventory On Hand | 643.99 | 344.59 |
Processa Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Processa Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Processa Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 12.39 | 2.16 | 2.95 | 2.37 | 1.76 | 1.67 | |
| Book Value Per Share | 29.04 | 61.17 | 33.27 | 9.28 | 3.81 | 3.62 | |
| Operating Cash Flow Per Share | (9.97) | (8.38) | (11.38) | (11.92) | (6.15) | (6.46) | |
| Pb Ratio | 12.39 | 2.16 | 2.95 | 2.37 | 1.76 | 1.67 | |
| Free Cash Flow Per Share | (9.97) | (8.38) | (11.38) | (11.92) | (6.15) | (6.46) | |
| Roic | (0.38) | (0.61) | (0.45) | (7.29) | (2.26) | (2.37) | |
| Net Income Per Share | (12.17) | (38.44) | (14.92) | (68.1) | (8.48) | (8.91) | |
| Payables Turnover | 11.61 | 47.2 | 55.43 | 84.03 | 7.12E-4 | 6.77E-4 | |
| Cash Per Share | 2.51 | 41.11 | 21.54 | 8.07 | 3.59 | 3.41 | |
| Pocfratio | (36.11) | (15.74) | (8.61) | (1.84) | (1.09) | (1.14) | |
| Interest Coverage | (28.07) | (107.36) | (53.84) | (33.5K) | (38.5K) | (36.6K) | |
| Pfcf Ratio | (36.11) | (15.74) | (8.61) | (1.84) | (1.09) | (1.14) | |
| Days Payables Outstanding | 31.44 | 7.73 | 6.59 | 4.34 | 512.3K | 538.0K | |
| Income Quality | 0.98 | 0.82 | 0.22 | 0.35 | 0.73 | 0.68 | |
| Roe | (0.42) | (0.63) | (0.45) | (7.34) | (2.23) | (2.34) | |
| Ev To Operating Cash Flow | (36.23) | (10.94) | (6.73) | (1.19) | (0.52) | (0.55) | |
| Pe Ratio | (29.58) | (3.43) | (6.57) | (0.32) | (0.79) | (0.83) | |
| Return On Tangible Assets | (1.36) | (2.71) | (0.88) | (6.36) | (1.92) | (2.02) | |
| Ev To Free Cash Flow | (36.23) | (10.94) | (6.73) | (1.19) | (0.52) | (0.55) | |
| Earnings Yield | (0.0338) | (0.29) | (0.15) | (3.1) | (1.27) | (1.2) | |
| Net Debt To E B I T D A | (0.11) | 2.68 | 1.48 | 0.32 | 0.4 | 0.42 | |
| Current Ratio | 0.85 | 13.27 | 18.87 | 8.4 | 7.71 | 3.97 | |
| Tangible Book Value Per Share | (5.91) | 37.58 | 22.75 | 9.28 | 3.81 | 4.0 | |
| Graham Number | 89.19 | 230.02 | 105.68 | 119.21 | 26.95 | 25.6 | |
| Shareholders Equity Per Share | 29.04 | 61.17 | 33.27 | 9.28 | 3.81 | 3.62 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.80) | Return On Assets (1.13) | Return On Equity (2.12) |
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.